A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2017
At a glance
- Drugs DEBIO 1562 (Primary) ; Rituximab
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Debiopharm; ImmunoGen
- 05 May 2016 Treatment arms changed from 1 to 2 arm, Time frame for primary endpoint (adverse events) changed from upto 100 months to 12 months.
- 05 May 2016 Status changed from not yet recruiting to recruiting.
- 05 May 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.